Photo by Maks Houbit

The limitations of current psychedelics

  • High-dose treatment (psychedelic-assisted psychotherapy)
    Psychedelic-assisted psychotherapy uses psychedelics in high doses, which is mentally demanding, has many contraindications and requires a considerable time commitment from a specially trained psychotherapist. It was designed for and will likely be suitable only for mental health disorders.
  • Low-dose treatment (microdosing)
    Microdosing uses low or “subperceptual” doses of psychedelics with some regularity, however, tolerance build up requires breaks between doses, so the effects are not constant. Clinical trials are still needed to show significant therapeutic efficacy and long-term safety (due to risk of 5-HT2B-mediated cardiotoxicity).
  • "Nonpsychedelic psychedelics” (psychoplastogens)
    Some researchers are exploring derivatives of psychedelics that apparently produce therapeutic action (in animal models) with no or minimal psychedelic effects. Because a body of evidence suggests psychedelic and therapeutic effects are closely correlated, these compounds likely act differently, lacking the psychedelic signature efficacy.

Founding team

Our experience in entrepreneurship, applied AI, software development & psychedelic drug design make us a well-rounded team, ready for the new era of drug discovery.

Dr Richard Dallaway

Combined expertise in machine learning and software engineering

Long history of successfully applying AI in different fields

Ing. Jáchym Fibír, MSc

Medicinal chemistry and pharmacology

4 years of research in psychedelic drug design, including an MSc at UCL

Suran Goonatilake, OBE

AI entrepreneur

Co-founder of AI startup Searchspace ($150m exit)

Professor at UCL Centre for AI

Scientific advisory board

Urszula Kozlowska Ph.D

Research on application of psychedelics as prospect therapeutic to stop the progress of neurodegeneration in dementia.
Polish Academy of Sciences
Dr Kozlowska is especially interested in the immunological aspects of the process of degeneration and regeneration of neural tissue. She has the experience in the bench-to-bedside process of novel therapeutic solutions discovery in basic, preclinical and clinical studies.

Assoc. Prof. Ing. Martin Kuchař, Ph.D

A bioorganic chemist, who has been trained in forensic toxicology and neuropsychopharmacological research for more than 10 years.
University of Chemistry and Technology, Prague
In the field of psychedelic substances he has a focus on the synthesis of pure alkaloids, their metabolism, and pharmacological characteristics with the potential to their use in psychiatric practice. He is an active member of the International Forensic Toxicological Society and tries to transpose current scientific knowledge into legal narcotics and psychotropic substances.

Prof. Ing. Daniel Svozil, Ph.D

Research in computational drug design and computational chemical biology.
University of Chemistry and Technology, Prague
In particular, chemical space exploration, de novo molecular design using deep learning approaches, synthetic accessibility prediction, molecular target identification and virtual screening of possibly active compounds.  Dan is the head of the Department of Informatics and Chemistry, creator and guarantor of BSc., MSc. and Ph.D. study programs in bioinformatics, head of the cheminformatics unit of the CZ-OPENSCREEN, the Czech national node of European research infrastructure in chemical biology EU-OPENSCREEN.


We have recently applied these advanced methods to biometrical discovery, and are now bringing this game changing technology to psychedelic medicine.

Our team has a stellar track record, building and exiting AI companies that have superhuman capabilities to detect complex patterns in data.

Dr. Richard Dallaway
Richard's expertise in AI spans 30 years from his undergraduate in AI, and his DPhil in machine learning at the University of Sussex. He has pioneered the use of deep-learning, evolutionary AI, among others, in fields as diverse as drug discovery to cancer diagnostics, to finding patterns in retail consumer purchase data. Richard combines his expertise in machine learning with deep knowledge of building and deploying large-scale enterprise software systems. He is a frequent speaker at conferences and a thought leader in the application of AI in scientific discovery.

Dr. Suran Goonatilake OBE
Suran is a visiting professor at the Computer Science Department at University College London (UCL) and co-founder of several deep-tech companies. He did his Phd in machine learning at UCL and along with fellow students co-founded Searchspace, a company that detects "unusual patterns" in financial transactions (e.g. insider-dealing), which was acquired by Warburg Pincus. He is co-editor of two books, "Intelligent Systems for Finance and Business" and "Intelligent Hybrid Systems". Suran was made an officer of the Order of the British Empire (OBE) in 2005.

Chris Davidson
Chris has been the co-founder of several tech companies, leading product management in digital media and face recognition offerings. He has business development and consulting experience in pharmaceutical, healthcare and technology industries. His academic background in is Physiological Sciences and Drug Pharmacology from University of Newcastle-upon-Tyne Medical School. As an active public speaker on physical and mental health, Chris is a passionate advocate of psychedelic-assisted psychotherapy with deep knowledge and understanding of the industry.



Follow us on LinkedIn and Twitter to stay updated. You can also message us there to say hello!

If you have enquires about April19, such as press or investment interest, please drop us an email at or use the form below.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.